-----

#### HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KHINDIVI<sup>®</sup> safely and effectively. See full prescribing information for KHINDIVI<sup>®</sup>.

#### KHINDIVI<sup>®</sup> (hydrocortisone) oral solution Initial U.S. Approval: 1952

KHINDIVI is a corticosteroid indicated as replacement therapy in pediatric patients 5 years of age and older with adrenocortical insufficiency. (1) Limitations of Use

KHINDIVI is not approved for increased dosing during periods of stress or acute events. Use a different hydrocortisone-containing drug product for stress dosing [see Warnings and Precautions (5.1)].

#### DOSAGE AND ADMINISTRATION

- Individualize the dose, using the lowest possible dosage. (2.1)
- When stress dosing is needed use a different hydrocortisone containing drug product. (2.1)
- The recommended starting replacement dosage of KHINDIVI is 8 to 10 mg/m<sup>2</sup> daily. Higher doses may be needed based on the patient's age and symptoms of the disease. Use of lower starting doses may be sufficient in patients with residual but decreased endogenous cortisol production. (2.2)
- Divide the total daily dose into 3 doses and administer 3 times daily. Older patients may have their daily dose divided by 2 and administered twice daily. (2.2)
- KHINDIVI contains the inactive ingredients polyethylene glycol 400, propylene glycol, and glycerin. If
  patients experience adverse reactions (i.e., hyperosmolarity, metabolic acidosis, hypoglycemia,
  hepato-renal injury, central nervous system toxicity, and gastrointestinal adverse reactions), consider
  discontinuation of KHINDIVI and switch to another hydrocortisone product. (2.3)
- When switching from other oral hydrocortisone formulations, use the same total daily hydrocortisone dosage. If symptoms of adrenal insufficiency occur, increase total daily dosage. (2.4)
- See the Full Prescribing Information for detailed dosing and administration instructions. (2)

#### ----- DOSAGE FORMS AND STRENGTHS

• Oral solution: 1 mg/mL. (3)

#### ----- CONTRAINDICATIONS

• Hypersensitivity to hydrocortisone or any component of KHINDIVI. (4)

#### ······ WARNINGS AND PRECAUTIONS ······

- <u>Adrenal Crisis</u>: Undertreatment, sudden discontinuation of therapy, or switching from another oral hydrocortisone formulation may lead to adrenocortical insufficiency, adrenal crisis and death. Adrenal crisis may also be induced by stress events such as infections or surgery. During periods of stress switch to another oral hydrocortisone product and increase the dose. Switch patients who are vomiting, severely ill or unable to take oral medications to parenteral corticosteroid formulations. (5.1)
- <u>Systemic Adverse Reactions Due to Inactive Ingredients</u>: KHINDIVI contains the inactive ingredients polyethylene glycol 400, propylene and glycol, and glycerin, which may cause hyperosmolarity, metabolic acidosis, hypoglycemia, hepato-renal injury, central nervous toxicity, gastrointestinal adverse reactions. Discontinue KHINDIVI and switch to another hydrocortisone product if these adverse reactions occur. (5.2)
- Immunosuppression and Increased Risk of Infection with Use of a Dosage Greater Than Replacement: Use of a greater than replacement dosage can suppress the immune system and increase the risks of new infections or exacerbation of latent infections with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic infections. Monitor patients for signs and symptoms of infections. (5.3)
- <u>Growth Retardation</u>: Long-term use in excessive doses may cause growth retardation. Use the minimum dosage of KHINDIVI to achieve desired clinical response and monitor the patient's growth. (5.4)
- <u>Cushing's Syndrome Due to Use of Excessive Doses of Corticosteroids</u>: Prolonged use with supraphysiologic doses may cause Cushing's syndrome. Monitor patients for signs and symptoms of Cushing's syndrome every 6 months. (5.5)

- <u>Decrease in Bone Mineral Density</u>: Corticosteroids decrease bone formation and increase bone resorption which may lead to inhibition of bone growth and development of osteoporosis. Use the minimum dosage of KHINDIVI to achieve desired clinical response.(5.6)
- <u>Psychiatric Adverse Reactions</u>: Use may be associated with severe psychiatric adverse reactions such as euphoria, mania, psychosis with hallucinations and delirium or depression. Symptoms typically emerge within a few days or weeks of starting the treatment. Most reactions resolve after either dose reduction or withdrawal, although specific treatment may be necessary. Monitor patients for behavioral and mood disturbances during treatment. Instruct caregivers and/or patients to seek medical advice if psychiatric symptoms develop. (5.7)
- <u>Ophthalmic Adverse Reactions</u>: Cataracts, glaucoma and central serous chorioretinopathy have been reported with prolonged use of high doses. Monitor patients for blurred vision or other visual disturbances and if they occur, refer them to an ophthalmologist. (5.8)
- <u>Gastrointestinal Adverse Reactions</u>: Increased risk in patients with certain gastrointestinal disorders. Signs and symptoms may be masked. (5.9)

Common adverse reactions for corticosteroids include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite, and weight gain. (6)

# To report SUSPECTED ADVERSE REACTIONS, contact Eton Pharmaceuticals, Inc. at 1-855-224-0233 or FDA at 1-800-FDA-1088 or <a href="https://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.

----- DRUG INTERACTIONS ------

- <u>CYP3A4 Inhibitors</u>: concomitant administration may require a decrease in the KHINDIVI dose. (7)
- <u>CYP3A4 Inducers</u>: concomitant administration may require an increase in the KHINDIVI dose. (7)
- <u>Estrogen and Estrogen-Containing Products</u>: concomitant administration may require an increase in the KHINDIVI dose. (7)
- <u>Antidiabetic agents</u>: excessive doses may increase blood glucose concentrations. Dose adjustment of antidiabetic agents may be required. (7)
- <u>NSAIDs</u>: concomitant administration increases risk of gastrointestinal adverse reactions. (7)

#### See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

#### Revised: 6/2025

#### **FULL PRESCRIBING INFORMATION: CONTENTS\***

#### **1 INDICATIONS AND USAGE**

#### **2 DOSAGE AND ADMINISTRATION**

- 2.1 Important Considerations for Dosing
- 2.2 Recommended Dosage and Administration

2.3 Discontinue KHINDIVI Due to Adverse Reactions Associated with Inactive Ingredients

2.4 Switching to KHINDIVI from Other Oral Hydrocortisone Formulations

#### **3 DOSAGE FORMS AND STRENGTHS**

#### **4 CONTRAINDICATIONS**

### **5 WARNINGS AND PRECAUTIONS**

- 5.1 Adrenal Crisis
- 5.2 Systemic Adverse Reactions Due to Inactive Ingredients

5.3 Immunosuppression and Increased Risk of Infection with Use of a Dosage Greater Than Replacement

- 5.4 Growth Retardation
- 5.5 Cushing's Syndrome Due to Use of Excessive Doses of Corticosteroids
- 5.6 Decrease in Bone Mineral Density
- 5.7 Psychiatric Adverse Reactions

- 5.8 Ophthalmic Adverse Reactions
- 5.9 Gastrointestinal Adverse Reactions
- 5.10 Risk of Kaposi's Sarcoma with Use of a Dosage Greater Than Replacement
- 5.11 Vaccination

## 6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

## 7 DRUG INTERACTIONS

## **8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use

### **10 OVERDOSAGE**

### **11 DESCRIPTION**

## **12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

## **13 NONCLINICAL TOXICOLOGY**

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

## **16 HOW SUPPLIED/STORAGE AND HANDLING**

## **17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

## FULL PRESCRIBING INFORMATION

## **1 INDICATIONS AND USAGE**

KHINDIVI is indicated as replacement therapy in pediatric patients 5 years of age and older with adrenocortical insufficiency.

### Limitations of Use

KHINDIVI is not approved for increased dosing during periods of stress or acute events. Use a different hydrocortisone-containing drug product for stress dosing [(see Warnings and Precautions (5.1)].

## 2 DOSAGE AND ADMINISTRATION

## 2.1 Important Considerations for Dosing

- Individualize the dose for each patient, using the lowest possible dosage.
- Monitor patients for symptoms of under and/or overtreatment including signs and symptoms of adrenocortical insufficiency, linear growth, and weight gain. Adjust doses accordingly.
- When stress dosing is needed (during episodes of acute febrile illness, gastroenteritis, surgery or major trauma) use a different hydrocortisone-containing

drug product. [see Warnings and Precautions (5.1)].

## 2.2 Recommended Dosage and Administration

- The recommended starting replacement dosage of KHINDIVI is 8 to 10 mg/m<sup>2</sup> daily administered orally with or without food. Higher doses may be needed based on the patient's age and symptoms of the disease. Use of lower starting dose may be sufficient in patients with residual but decreased endogenous cortisol production.
- Round the dose to the nearest 0.5 mg or 1 mg.
- Divide the total daily dose into 3 doses and administer 3 times daily. Older pediatric patients may have their daily dose divided by 2 and administered twice daily.
- Administer KHINDIVI using the oral syringe provided by the pharmacy.
- KHINDIVI may be administered through a gastric tube. Flush gastric tube with 20 mL of water to ensure the entire dose is delivered.

# 2.3 Discontinue KHINDIVI Due to Adverse Reactions Associated with Inactive Ingredients

• KHINDIVI contains the inactive ingredients polyethylene glycol 400, propylene glycol, and glycerin, which have been associated with hyperosmolarity, metabolic acidosis, hypoglycemia, hepato-renal injury, central nervous system toxicity, and gastrointestinal adverse reactions. If patient presents with adverse reactions that could be related to these conditions, monitor the patient, and consider discontinuation of KHINDIVI and switching to another hydrocortisone product [see Warnings and Precautions (5.2)].

## 2.4 Switching to KHINDIVI from Other Oral Hydrocortisone Formulations

• When switching patients to KHINDIVI from other oral hydrocortisone formulations to KHINDIVI use the same total daily hydrocortisone dosage. After switching to KHINDIVI, monitor patients for symptoms of adrenocortical insufficiency. If symptoms of adrenal insufficiency occur after switching, increase the total daily dosage of KHINDIVI [see Dosage and Administration (2.2) and Warnings and Precautions (5.1, 5.2)].

## **3 DOSAGE FORMS AND STRENGTHS**

KHINDIVI oral solution, 1 mg/mL is a clear, colorless to slightly yellow colored viscous oral solution.

## **4 CONTRAINDICATIONS**

KHINDIVI is contraindicated in patients with hypersensitivity to hydrocortisone or to any component of KHINDIVI. Reactions have included anaphylaxis in patients receiving corticosteroids [see Adverse Reactions (6.2)].

## **5 WARNINGS AND PRECAUTIONS**

## 5.1 Adrenal Crisis

Undertreatment with KHINDIVI or sudden discontinuation of therapy with KHINDIVI may

lead to adrenocortical insufficiency, adrenal crisis, and death. Adrenal crisis may also be induced by stress events such as infections or surgery when patients require higher doses of corticosteroids. Symptoms of adrenocortical insufficiency include poor feeding, fatigue, low muscle tone, joint pain, nausea, vomiting, hypoglycemia, low blood pressure and electrolyte disturbances.

During periods of stress (e.g., infections, surgery), switch to another oral hydrocortisone product and increase the dose, if oral medications are tolerated. Switch patients who are vomiting, severely ill, or unable to take oral medications to parenteral corticosteroid formulations without delay. Once the patient recovers, gradually reduce the steroid dosage used during the acute event and do not switch back to KHINDIVI until the maintenance dosage can be resumed.

KHINDIVI is not approved for stress dosing. KHINDIVI contains inactive ingredients polyethylene glycol 400, propylene glycol, and glycerin at levels that individually or in combination may result in hyperosmolarity, metabolic acidosis, hypoglycemia, hepatorenal injury, central nervous system toxicity (e.g., seizure and coma) and/or gastrointestinal adverse reactions [see Warnings and Precautions (5.2)]. Use of KHINDIVI for stress dosing will result in a greater exposure to inactive ingredients and may increase the risk of these adverse reactions.

When switching patients to KHINDIVI from other oral hydrocortisone formulations, consider the potential for dosing inaccuracy if other oral hydrocortisone formulations have been manipulated (e.g., split or crushed tablets, compounded formulations). Manipulation of oral hydrocortisone formulations may result in a relative difference in hydrocortisone exposure when using the same dosage to initiate KHINDIVI treatment. Monitor patients after switching to KHINDIVI to ensure KHINDIVI is providing the same level of hydrocortisone exposure as the previously used oral hydrocortisone formulation. If symptoms of adrenal insufficiency occur, increase the total daily dosage of KHINDIVI.

### 5.2 Systemic Adverse Reactions Due to Inactive Ingredients

### <u>Hyperosmolarity</u>

KHINDIVI is not approved in pediatric patients less than 5 years of age. KHINDIVI contains the inactive ingredients polyethylene glycol 400, propylene glycol, and glycerin, which undergo substantial systemic absorption. These inactive ingredients, individually or in combination may increase plasma osmolarity in all pediatric patients, especially in pediatric patients less than 5 years of age due to incomplete maturity of the alcohol dehydrogenase enzyme that metabolizes propylene glycol and polyethylene glycol 400.

Monitor pediatric patients using KHINDIVI for signs and symptoms consistent with hyperosmolarity. Discontinue KHINDIVI and switch to another hydrocortisone formulation if this occurs.

### Metabolic Acidosis and Other Adverse Reactions

KHINDIVI contains the inactive ingredient polyethylene glycol 400 and propylene glycol that may result in metabolic acidosis, hypoglycemia, hepato-renal injury, and central nervous system toxicity (e.g., seizure and coma). These adverse reactions may increase the risk of adrenal crisis [see Warnings and Precautions (5.1)]. Monitor laboratory values and for physical signs and symptoms of these adverse reactions. Discontinue KHINDIVI and switch to another hydrocortisone formulation if these adverse reactions occur.

#### Laxative Effects Due to Inactive Ingredients

KHINDIVI contains the inactive ingredients polyethylene glycol 400 and glycerin, which alone or in combination, may cause gastrointestinal irritation resulting in vomiting and/or diarrhea. These gastrointestinal reactions may increase the risk of adrenal crisis in patients with adrenal insufficiency [see Warnings and Precautions (5.1)]. Monitor for signs or symptoms of gastrointestinal irritation and associated fluid and electrolyte abnormalities. Discontinue KHINDIVI and switch to another hydrocortisone formulation if these adverse reactions occur.

# 5.3 Immunosuppression and Increased Risk of Infection with Use of a Dosage Greater Than Replacement

Use of the recommended dosage of KHINDIVI [see Dosage and Administration (2.1, 2.2)] as a replacement therapy in pediatric patients with adrenocortical insufficiency is not expected to cause immunosuppression or increase the risk of infection. The use of a greater than replacement dosage can suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. The use of KHINDIVI at greater than replacement dosage can:

- Reduce resistance to new infections
- Exacerbate existing infections
- Increase the risk of disseminated infections
- Increase the risk of reactivation or exacerbation of latent infections
- Mask some signs of infection

Infections associated with the use of corticosteroids at a greater than replacement dosage range from mild to severe or fatal, and the rate of infectious complications increases with increasing corticosteroid dosages.

Monitor for the development of infection and consider KHINDIVI dosage reduction as needed [see Warnings and Precautions (5.1)].

## 5.4 Growth Retardation

Long-term use of corticosteroids in excessive doses may cause growth retardation in pediatric patients. Historical cohorts of adults treated from childhood for congenital adrenal hyperplasia have been found to have growth retardation. Effects on linear growth are less likely when using corticosteroids as replacement therapy. Use the minimum dosage of KHINDIVI to achieve desired clinical response and monitor the patient's growth.

## 5.5 Cushing's Syndrome Due to Use of Excessive Doses of Corticosteroids

Prolonged use of corticosteroids in supraphysiologic doses may cause Cushing's syndrome. Symptoms and signs of Cushing's syndrome include weight gain, decreased height velocity, hyperglycemia, hypertension, edema, easy bruising, muscle weakness, red round face, depression, or mood swings. Monitor patients for signs and symptoms of Cushing's syndrome every 6 months.

## 5.6 Decrease in Bone Mineral Density

Corticosteroids decrease bone formation and increase bone resorption which may lead

to development of osteoporosis. Historical cohorts of adults treated from childhood for congenital adrenal hyperplasia have been found to have reduced bone mineral density and increased fracture rates. Use the minimum dosage of KHINDIVI to achieve desired clinical response.

## 5.7 Psychiatric Adverse Reactions

Corticosteroid use may be associated with severe psychiatric adverse reactions. Euphoria, mania, psychosis with hallucinations and delirium or depression have been seen in patients at replacement doses of hydrocortisone [see Adverse Reactions (6)]. Symptoms typically emerge within a few days or weeks of starting the treatment. Risks may be higher with high doses, although dose levels do not allow prediction of the onset, type, severity, or duration of reactions. Most reactions resolve after either dose reduction or withdrawal, although specific treatment may be necessary. Monitor patients for behavioral and mood disturbances during treatment with KHINDIVI. Instruct caregivers and/or patients to seek medical advice if psychiatric symptoms develop.

## 5.8 Ophthalmic Adverse Reactions

Ophthalmic effects, such as cataract, glaucoma or central serous chorioretinopathy have been reported with prolonged use of corticosteroids in high doses. Monitor patients for blurred vision or other visual disturbances. If patients develop ophthalmic adverse reactions, refer them to an ophthalmologist for further evaluation.

## 5.9 Gastrointestinal Adverse Reactions

### **Gastrointestinal Perforation**

There is an increased risk of gastrointestinal perforation in patients with certain gastrointestinal disorders. Signs of gastrointestinal perforation, such as peritoneal irritation may be masked in patients receiving corticosteroids. Corticosteroids should be used with caution if there is a probability of impending perforation, abscess, or other pyogenic infections, diverticulitis, fresh intestinal anastomoses, and active or latent peptic ulcer.

### Concomitant Use with Non-Steroidal Anti-Inflammatory Drugs

Concurrent administration of corticosteroids with non-steroidal anti-inflammatory drugs (NSAIDS) may increase the risk of gastrointestinal adverse reactions. Monitor patients receiving corticosteroids and concomitant NSAIDS for gastrointestinal adverse reactions *[see Drug Interactions (7)]*.

# 5.10 Risk of Kaposi's Sarcoma with Use of a Dosage Greater Than Replacement

Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions at a dosage greater than replacement (supraphysiologic dosage). If patients take a supraphysiologic chronic dosage of KHINDIVI, they are at increased risk of developing Kaposi's sarcoma.

## 5.11 Vaccination

Administration of live vaccines may be acceptable in KHINDIVI-treated pediatric patients with adrenocortical insufficiency who receive replacement corticosteroids.

## **6 ADVERSE REACTIONS**

The following serious adverse reactions are described here and elsewhere in the label:

- Adrenal Crisis [see Warnings and Precautions (5.1)]
- Systemic Adverse Reactions Due to Inactive Ingredients [see Warnings and Precautions (5.2)]
- Immunosuppression and Increased Risk of Infection with Use of a Dosage Greater Than Replacement [see Warnings and Precautions (5.3)]
- Growth Retardation [see Warnings and Precautions (5.4)]
- Cushing's Syndrome Due to Use of Excessive Doses of Corticosteroids [see Warnings and Precautions (5.5)]
- Decrease in Bone Mineral Density [see Warnings and Precautions (5.6)]
- Psychiatric Adverse Reactions [see Warnings and Precautions (5.7)]
- Ophthalmic Adverse Reactions [see Warnings and Precautions (5.8)]
- Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.9)]
- Risk of Kaposi's Sarcoma with Use of Dosage Greater than Replacement [see Warnings and Precautions (5.10)]
- Vaccinations [see Warnings and Precautions (5.11)]

## 6.1 Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of oral hydrocortisone was evaluated in an uncontrolled, open-label, singlearm clinical study in 18 pediatric patients with adrenocortical insufficiency treated with oral hydrocortisone granules. Adrenocortical insufficiency was due to congenital adrenal hyperplasia in 17 patients and to hypopituitarism in one patient. All patients received at least one dose of hydrocortisone granules. The age ranged from 36 days to 5.7 years at start of treatment; 8 patients were female and 10 were male; 100% were White. Adverse reactions that were reported in two or more patients ( $\geq$  11%) are shown in Table 1.

#### Table 1: Adverse Reactions Occurring in ≥11% of Pediatric Patients with Adrenocortical Insufficiency Treated with Hydrocortisone Granules for up to 29 Months

Advarsa Baactions	N=18
	n (%)
Pyrexia	10 (56)
Gastroenteritis	9 (50)
Viral upper respiratory tract infection	8 (44)
Vomiting	7 (39)
Viral infection	6 (33)
Conjunctivitis	5 (28)
Otitis media viral	3 (17)
Tonsillitis	3 (17)

Body temperature increased	2 (11)
Bronchitis	2 (11)
Dental caries	2 (11)
Diarrhea	2 (11)
Genitourinary operation	2 (11)
Pharyngitis	2 (11)
Respiratory tract infection	2 (11)
Rhinitis	2 (11)

## 6.2 Postmarketing Experience

The following adverse reactions seen in pediatric and adult patients associated with the use of corticosteroids were identified in the literature and from postmarketing reports. Because some of these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Common adverse reactions for corticosteroids include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain.

Allergic Reactions: Anaphylaxis, angioedema

*Cardiovascular:* Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction, pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis

*Dermatologic:* Acne, allergic dermatitis, cutaneous and subcutaneous atrophy, dry scalp, edema, facial erythema, hyper or hypo-pigmentation, impaired wound healing, increased sweating, petechiae and ecchymoses, rash, sterile abscess, striae, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria

*Endocrine:* Abnormal fat deposits, decreased carbohydrate tolerance, development of Cushingoid state, hirsutism, manifestations of latent diabetes mellitus and increased requirements for insulin or oral hypoglycemic agents in diabetics, menstrual irregularities, moon faces, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery or illness), suppression of growth in pediatric patients

*Fluid and Electrolyte Disturbances:* Fluid retention, potassium loss, hypertension, hypokalemic alkalosis, sodium retention

*Gastrointestinal:* Abdominal distention, elevation in serum liver enzymes levels (usually reversible upon discontinuation), hepatomegaly, hiccups, malaise, nausea, pancreatitis, peptic ulcer with possible perforation and hemorrhage, ulcerative esophagitis

General: Increased appetite and weight gain

Metabolic: Negative nitrogen balance due to protein catabolism

*Musculoskeletal:* Osteonecrosis of femoral and humeral heads, Charcot-like arthropathy, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long

bones, steroid myopathy, tendon rupture, vertebral compression fractures

*Neurological:* Arachnoiditis, convulsions, depression, emotional instability, euphoria, headache, increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually following discontinuation of treatment, insomnia, meningitis, mood swings, neuritis, neuropathy, paraparesis/paraplegia, paresthesia, personality changes, sensory disturbances, vertigo

*Ophthalmic:* Exophthalmos, glaucoma, increased intraocular pressure, posterior subcapsular cataracts, and central serous chorioretinopathy

Reproductive: Alteration in motility and number of spermatozoa

## 7 DRUG INTERACTIONS

CYP3A4 Inhib	itors
Clinical Impact:	Hydrocortisone is metabolized by cytochrome P450 3A4 (CYP3A4). Concomitant administration of inhibitors of CYP3A4 may lead to increases in serum concentrations of KHINDIVI and increase the risk of adverse reactions associated with the use of excessive doses.
Intervention:	Concomitant use of CYP3A4 inhibitors may require a decrease in the KHINDIVI dose.
Examples:	<i>Anti-fungals:</i> itraconazole, posaconazole, voriconazole <i>Antibiotics:</i> erythromycin and clarithromycin <i>Antiretrovirals:</i> ritonavir Grapefruit juice
CYP3A4 Induc	Cers
Clinical Impact:	Hydrocortisone is metabolized by cytochrome P450 3A4 (CYP3A4). Concomitant administration of inducers of CYP3A4 may lead to decreases in serum concentrations of KHINDIVI and increase the risk of adverse reactions, including adrenal crisis.
Intervention:	Concomitant use of CYP3A4 inducers may require an increase in the KHINDIVI dose.
Examples:	<i>Anticonvulsants</i> : phenytoin, carbamazepine and oxcarbazepine <i>Antibiotics</i> : rifampicin and rifabutin <i>Barbiturates:</i> phenobarbital and primidone <i>Antiretrovirals</i> : efavirenz and nevirapine
Estrogen and	Estrogen-Containing Products
Clinical Impact:	Oral estrogen and estrogen-containing oral contraceptives may interact with hydrocortisone by increasing serum cortisol- binding globulin (CBG) concentration. Concomitant use may reduce the efficacy of KHINDIVI by binding and delaying or preventing absorption.
Intervention:	Concomitant use of estrogen/estrogen containing products may require an increase in the KHINDIVI dose.

Table 2: Drug Interactions with KHINDIVI

#### Antidiabetic Agents

Clinical Impact:	Corticosteroids in supraphysiologic doses may increase blood glucose concentrations.
Intervention:	Use of KHINDIVI in supraphysiologic doses may require a dose adjustment of antidiabetic agents.
Anticoagulant	Agents
Clinical Impact:	Concomitant use of warfarin and corticosteroids usually results in inhibition of response to warfarin, although there have been some conflicting reports.
Intervention:	Monitor coagulation indices in patients receiving KHINDIVI and concomitant warfarin to maintain the desired anticoagulant effect.
Cyclosporine	
Clinical Impact:	Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with concurrent use.
Intervention:	Monitor patients receiving KHINDIVI and concomitant cyclosporine.
Nonsteroidal /	Anti-inflammatory Drugs (NSAIDs)
Clinical Impact:	Concomitant use of NSAIDs and corticosteroids increases the risk of gastrointestinal adverse reactions. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids; this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.
Intervention:	Monitor patients receiving KHINDIVI and concomitant NSAIDs.

## **8 USE IN SPECIFIC POPULATIONS**

### 8.1 Pregnancy

#### <u>Risk Summary</u>

Untreated adrenocortical insufficiency in pregnancy can result in a high rate of complications, including maternal mortality. The use of physiologic doses of hydrocortisone is not expected to cause major birth defects, miscarriage and adverse maternal and fetal outcomes. Available data from observational studies with hydrocortisone use in pregnancy have not identified a clear drug- associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes (*see Data*).

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.

#### <u>Data</u>

#### Human Data

Available data from observational studies with hydrocortisone use in pregnant women

have not identified a clear drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Evidence from published epidemiologic studies suggest that there may be a small increased risk of cleft lip with or without cleft palate associated with first trimester systemic corticosteroid use in pregnant patients. However, the data are limited and report inconsistent findings, and studies have important methodological limitations, including non-randomized design, retrospective data collection, lack of dose-response data and the inability to control for confounders, such as underlying maternal disease and use of concomitant medications. In addition, unlike other corticosteroids, hydrocortisone is enzymatically deactivated by the placenta and therefore limits fetal exposure.

#### Animal Data

Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. Animal studies in which corticosteroids have been given to pregnant mice, rats and rabbits without adrenocortical insufficiency have yielded an increased incidence of cleft palate in the offspring.

## 8.2 Lactation

#### <u>Risk Summary</u>

Cortisol is present in human milk. The use of hydrocortisone at a physiologic dose for adrenocortical insufficiency is not expected to adversely affect the breastfed infant or milk production. There are no data on the presence of hydrocortisone in breast milk, the effect on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for KHINDIVI and any potential adverse effects on the breastfed infant from KHINDIVI or from the underlying maternal condition.

### 8.4 Pediatric Use

The safety and effectiveness of KHINDIVI have been established in pediatric patients 5 years of age and older for replacement therapy of adrenocortical insufficiency and the information on this use is discussed throughout the labeling. Use of KHINDIVI for this indication is supported by findings of safety and efficacy in other approved hydrocortisone products, including supportive pharmacokinetic and safety data in pediatric patients with adrenocortical insufficiency.

KHINDIVI is not approved in pediatric patients less than 5 years of age. KHINDIVI contains the inactive ingredients polyethylene glycol 400, propylene glycol, and glycerin, which undergo substantial systemic absorption. These inactive ingredients, individually or in combination, may increase plasma osmolarity in all pediatric patients, especially in pediatric patients less than 5 years of age due to incomplete alcohol dehydrogenase maturity [see Warnings and Precautions (5.2)].

When prescribing KHINDIVI in pediatric patients 5 years of age and older, consider the combined daily amount of polyethylene glycol 400, propylene glycol, and glycerin from all sources including KHINDIVI and other drugs with inactive ingredients utilizing the same metabolic pathways as these inactive ingredients, which may increase exposure and lead to an increased risk of systemic toxicity [see Warnings and Precautions (5.2)].

## **10 OVERDOSAGE**

Treatment of acute overdosage is by supportive and symptomatic therapy.

## **11 DESCRIPTION**

KHINDIVI contains hydrocortisone, a corticosteroid, also known as cortisol. The chemical name of hydrocortisone is  $11\beta$ , $17\alpha$ ,21-trihydroxy-pregn-4-ene-3,20-dione and it has the chemical formula of C<sub>21</sub>H<sub>30</sub>O<sub>5</sub>, and molecular weight of 362 g•mol<sup>-1</sup>. Hydrocortisone is a white or almost white powder soluble in the pH range of 1-7.

#### Structural formula of hydrocortisone:



KHINDIVI is a clear, colorless to slightly yellow colored viscous solution of hydrocortisone available for oral administration in a concentration of 1 mg/mL. The inactive ingredients are berry flavor, butylated hydroxyanisole, ethyl maltol, glycerin (623 mg/mL), methylparaben, propylparaben, polyethylene glycol 400 (500 mg/mL), propylene glycol (50 mg/mL), and sucralose.

## **12 CLINICAL PHARMACOLOGY**

### 12.1 Mechanism of Action

Hydrocortisone is a glucocorticoid. Glucocorticoids, adrenocortical steroids, cause varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

### **12.2 Pharmacodynamics**

Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have saltretaining properties, are used as replacement therapy in adrenocortical deficiency states.

### **12.3 Pharmacokinetics**

<u>Absorption</u>

Following oral administration of KHINDIVI (5 mg) in dexamethasone-suppressed healthy adult volunteers under fasted conditions, mean (range) maximum plasma concentration ( $C_{max}$ ) of hydrocortisone is 152 (98-210) ng/mL. Mean (range) time to reach maximum concentration ( $T_{max}$ ) is 0.5 (0.25-0.75) hours.

#### Effect of Food

No clinically significant differences in KHINDIVI pharmacokinetics were observed following administration of a high-fat meal.

#### <u>Distribution</u>

90% or more of circulating hydrocortisone is reversibly bound to protein.

The binding is accounted for by two protein fractions. One, corticosteroid-binding globulin is a glycoprotein; the other is albumin.

Following administration of 5 mg Hydrocortisone oral solution in dexamethasonesuppressed healthy adult volunteers under fasted conditions, mean (range) apparent (oral) volume of distribution (Vd/F) of hydrocortisone is 23 (5-59) L.

#### **Elimination**

Hydrocortisone is metabolized in the liver and most body tissues to hydrogenated and degraded forms such as tetrahydrocortisone and tetrahydrocortisol which are excreted in the urine, mainly conjugated as glucuronides, together with a very small proportion of unchanged hydrocortisone.

Following administration of 5 mg Hydrocortisone oral solution in dexamethasonesuppressed healthy adult volunteers under fasted conditions, mean (range) terminal half-life of hydrocortisone is about 0.95 (0.3-2.3) hours.

## **13 NONCLINICAL TOXICOLOGY**

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No adequate studies in animals have been conducted with hydrocortisone to evaluate carcinogenic or mutagenic potential. Corticosteroids have been shown to impair fertility in male rats.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

KHINDIVI is supplied as a colorless to slightly yellow colored, clear viscous solution:

Strength	Volume in Bottle	NDC
1 mg/mL	473 mL	71863-116-16

Store at 2°C to 25°C (36°F to 77°F). Excursions permitted to 30°C (86°F) [see USP refrigerated and controlled room temperature]. Protect from light and heat.

Product must be used within 120 days of first opening. If not used within 120 days, the unused portion must be discarded.

## **17 PATIENT COUNSELING INFORMATION**

Advise patients and/or caregivers to read the FDA-approved patient labeling (Medication Guide).

#### Administration Information

Instruct patients and/or caregivers to use an oral dosing syringe to correctly measure the prescribed amount of medication. Inform patients and/or caregivers that oral dosing syringes may be obtained from their pharmacy.

Advise patients and/or caregivers to take a sip of water immediately following administration to ensure all the solution has been swallowed.

For administration through a gastric tube, flush with 20 mL of water to ensure that the entire dose is delivered [see Dosage and Administration (2.2)].

#### <u>Adrenal Crisis</u>

Inform patients and/or caregivers that undertreatment or sudden discontinuation of KHINDIVI or switching to KHINDIVI from another oral hydrocortisone formulation, may lead to adrenocortical insufficiency, adrenal crisis, and death.

Inform patients and/or caregivers to switch to another oral hydrocortisone product and increase the dose during periods of stress, and not to use KHINDIVI for increased dosing during period of stress or acute events due to increased risk of systemic and gastrointestinal adverse reactions.

Inform the caregiver that potential dosing inaccuracy of the manipulated oral hydrocortisone formulation (e.g., split or crushed tablets, compounded formulations) may result in dosing differences when switching to KHINDIVI which may require dose adjustments. Advise caregivers to watch the patient for symptoms of adrenocortical insufficiency during the days after switching to KHINDIVI. Inform patient and/or caregiver to contact their healthcare provider if they have symptoms of adrenocortical insufficiency, prolonged vomiting, are severely ill or are unable to take oral medications *[see Warnings and Precautions (5.1)]*.

#### Systemic Adverse Reactions Due to Inactive Ingredients

Inform patients and/or caregivers that some inactive ingredients in KHINDIVI may increase the risk for hyperosmolarity, metabolic acidosis, loose stools, diarrhea, and other systemic adverse reactions, which may increase the risk of adrenal crisis. Patients and/or caregivers should contact the healthcare provider if patients have altered mental status, abnormal urine output, or are severely ill *[see Warnings and Precautions (5.2)]*.

#### Immunosuppression and Increased Risk of Infections

Advise patients and/or caregivers that greater than replacement dosage of corticosteroids can suppress the immune system and increase the risk of infections. Instruct patients and/or caregivers to contact their healthcare provider if they develop any infections [see Warnings and Precautions (5.3)].

#### Growth Retardation

Discuss with caregivers that long-term use of corticosteroids in excessive doses may cause growth retardation in pediatric patients [see Warnings and Precautions (5.4)].

#### Cushing's Syndrome

Inform patients and/or caregivers that prolonged use of corticosteroids in supraphysiologic doses may cause Cushing's syndrome and that symptoms and signs include weight gain, decreased height velocity, hyperglycemia, hypertension, edema, easy bruising, muscle weakness, red round face, depression, or mood swings [see Warnings and Precautions (5.5)].

#### Decrease in Bone Mineral Density

Inform patients and/or caregivers that corticosteroids decrease bone formation and increase bone resorption that may lead to osteoporosis [see Warnings and Precautions (5.6)].

#### Psychiatric Adverse Reactions

Advise patients and/or caregivers that corticosteroid use may be associated with severe psychiatric adverse reactions such as euphoria, mania, psychosis with hallucinations or depression. Instruct caregivers and/or patients to seek medical advice if psychiatric symptoms develop [see Warnings and Precautions (5.7)].

#### **Ophthalmic Adverse Reactions**

Inform patients and/or caregivers that ophthalmic effects such as cataract, glaucoma or central serous chorioretinopathy have been reported with prolonged use of high-dose corticosteroids. Instruct patients or caregivers to report any blurred vision or visual disturbances to their healthcare provider [see Warnings and Precautions (5.8)].

#### Gastrointestinal Adverse Reactions

Discuss with patients and/or healthcare providers that use of corticosteroids may increase risk of gastrointestinal perforation in certain gastrointestinal disorders [see Warnings and Precautions (5.9)].

### Risk of Kaposi's Sarcoma

Inform patients that they are at risk of developing Kaposi's sarcoma [see Warnings and Precautions (5.10)].

### Vaccination

Inform patients and/or caregivers that administration of live vaccine may be acceptable [see Warnings and Precautions (5.11)].

KHINDIVI is manufactured for Eton Pharmaceuticals, Inc. by Tulex Pharmaceuticals, Inc., 5 Cedarbrook Dr., Cranbury, NJ 08512, USA.

KHINDIVI<sup>®</sup> is a registered trademark of Eton Pharmaceuticals, Inc.

KHINDIVI is covered by the following US patents: 11,904,046, and 12,133, 914.

PL-1-1.0

## Medication Guide

KHINDIVI® (kɪn-dɪv-i) (hydrocortisone) oral solution

Read this Medication Guide before you start giving KHINDIVI to your child, and each time your child gets a refill. There may be new information. This information does not take the

place of talking to your healthcare provider about your child's medical condition or treatment.

## What is the most important information I should know about KHINDIVI? KHINDIVI may cause serious side effects, including:

**Adrenal gland problems**. Not giving enough KHINDIVI, stopping KHINDIVI, or switching to KHINDIVI after taking another hydrocortisone medicine (the same class of medicines as KHINDIVI) by mouth, can cause serious and life-threatening adrenal gland problems including death. Do not stop giving KHINDIVI without talking to your healthcare provider. Tell your healthcare provider if your child has any of these symptoms:

- loss of appetite
- joint pain
- nausea
- low blood sugar
   feeling lighthead
- feeling lightheaded or dizzy

• weakness

• fatigue

- vomiting
- problems with body salt (electrolyte) levels

Your healthcare provider will change the dose of KHINDIVI depending on your child's size. During episodes of acute infections, surgery, or major trauma, your healthcare provider may prescribe your child a different hydrocortisone medicine and increase the dose. If your child is vomiting, severely ill, or unable to take medicines by mouth, your healthcare provider may use corticosteroid medicines that are given directly into the bloodstream instead.

The amount of hydrocortisone in a dose of KHINDIVI may not be the same as in previous hydrocortisone medicines that your child takes by mouth if these oral hydrocortisone medicines have been changed (for example, crushed or compounded). When switching to KHINDIVI, your healthcare provider may need to prescribe a starting dose of KHINDIVI that is different from previous hydrocortisone medicines that your child may have been taking by mouth. Watch your child closely after being switched to KHINDIVI and contact your healthcare provider if your child has any symptoms of adrenal gland problems. Your healthcare provider may need to change the dose of KHINDIVI.

# See "What are the possible side effects of KHINDIVI?" for more information about side effects.

## What is KHINDIVI?

KHINDIVI is a prescription medicine that contains a medicine hydrocortisone. Hydrocortisone belongs to a group of medicines known as corticosteroids.

Hydrocortisone is a synthetic version of the hormone cortisol. Cortisol is made naturally by the adrenal glands in the body. KHINDIVI (hydrocortisone) is a man-made (synthetic) corticosteroid used to replace the body's cortisol when the adrenal glands do not make enough (adrenal insufficiency) in children from 5 to 17 years of age.

#### Who should not take or be given KHINDIVI? Do not give your child KHINDIVI if they:

- are allergic to hydrocortisone or any of the ingredients in KHINDIVI. See the end of this Medication Guide for a complete list of ingredients in KHINDIVI.
- have any reaction like swelling or shortness of breath after being given KHINDIVI. Get medical help right away and tell your healthcare provider as soon as possible as these can be signs of an allergic reaction.

What should I tell my healthcare provider before giving KHINDIVI? Before you give your child KHINDIVI, tell your healthcare provider about all of

## your child's medical conditions, including if they:

- are feeling unwell, or their body is under stress because of surgery or trauma. Your healthcare provider may prescribe your child a different hydrocortisone medicine for a short period of time.
- have a fever or infection.
- have nausea, vomiting, or diarrhea.
- are due for vaccinations. Taking KHINDIVI should not stop your child from being vaccinated. Tell your healthcare provider when your child is due for vaccinations.
- are scheduled for surgery.
- cannot swallow medicines by mouth or are fed through a gastric tube.
- are pregnant or plan to become pregnant. It is not known if KHINDIVI will harm your child's unborn baby. Talk to your child's healthcare provider if your child is pregnant or plans to become pregnant.
- are breastfeeding or plan to breastfeed. It is not known if KHINDIVI passes into the breast milk. You and your child's healthcare provider should decide if your child will receive KHINDIVI while your child breastfeeds.

## Tell your healthcare provider about all the medicines your child takes,

including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Some medicines, food and drink can affect the way that KHINDIVI works and may mean that your healthcare provider needs to change your child's dose of KHINDIVI.

## Especially tell your healthcare provider if your child:

- takes medicines used to treat fungal infections such as itraconazole, posaconazole, and voriconazole.
- takes medicines used to treat bacterial infections such as rifampicin, rifabutin, erythromycin, and clarithromycin.
- takes medicines used to treat human immunodeficiency virus (HIV) infection and AIDS such as ritonavir, efavirenz, and nevirapine.
- takes seizure medicines such as phenytoin, carbamazepine, oxcarbazepine, phenobarbital, and primidone.
- takes estrogen.
- takes warfarin.
- takes nonsteroidal anti-inflammatory medicines such as aspirin and ibuprofen.
- takes cyclosporine.
- takes diabetes medicines.
- drinks grapefruit juice.

Know the medicines your child takes. Keep a list of them to show your healthcare provider and pharmacist when your child gets a new medicine.

## How should I give KHINDIVI?

- Give KHINDIVI exactly as prescribed by your healthcare provider.
- Give KHINDIVI by mouth with or without food.
- Give a sip of water right away after giving KHINDIVI to make sure that all of the medicine has been swallowed.
- Give KHINDIVI using the oral syringe provided by the pharmacy.
- Do not stop giving KHINDIVI without talking to your healthcare provider. See "What is the most important information I should know about KHINDIVI?"
- KHINDIVI can be given through a gastric tube. After KHINDIVI is given through the

gastric tube, flush the gastric tube with 20 mL of water right away to make sure all the medicine has been given.

• If your child takes too much KHINDIVI, call your healthcare provider right away or go to the nearest emergency room.

## What are the possible side effects of KHINDIVI? KHINDIVI may cause serious side effects, including:

- See "What is the most important information I should know about KHINDIVI?"
- Hyperosmolarity, metabolic acidosis, and stomach problems. Some of the ingredients in KHINDIVI may increase the risk for imbalance of salts and other substances in your blood leading to fluid shifts (hyperosmolarity), too much acid in the blood (metabolic acidosis), vomiting, loose stools, diarrhea, and other side effects, which may increase the risk of adrenal gland problems. Tell your healthcare provider if your child has confusion (altered mental status), urine output that is not normal, or is severely ill. Your healthcare provider may prescribe your child a different hydrocortisone medicine.
- Weakened immune system and increased risk of infections. Taking too much KHINDIVI can weaken your body's immune system and increase your chance of getting infections. Tell your healthcare provider if your child develops any infections or has any of these symptoms:
  - fever
  - cough

• stomach area (abdominal) pain

- flu-like symptoms
- Slowed growth in children. Taking too much KHINDIVI and taking it for long periods of time can affect your child's growth. Tell your healthcare provider if you are worried about your child's growth. Your healthcare provider will change the dose depending on your child's size.

• diarrhea

• **Cushing's syndrome.** Taking too much KHINDIVI and taking it for long periods of time can cause Cushing's syndrome. Tell your healthcare provider if your child has any of these symptoms:

0	weight gain	0	high blood			0	muscle	0	feeling
0	slowed growth in height	0	sugar high blood pressure	0 0	swelling bruising easily	0	weakness red, round face	0	depressed mood swings

- Weak, brittle, or soft bones. KHINDIVI can affect your child's bones. Your healthcare provider will change the dose depending on your child's size and will monitor your child's growth and bones.
- **Changes in behavior.** Your child's behavior may change after starting or during treatment with KHINDIVI. Tell your healthcare provider right away if your child develops any changes in behavior including:
  - strong feelings of happiness and excitement.
  - overexcited and overactive.
  - loss of contact with reality, with feelings that are not real, and mental confusion.
  - depression.

- **Vision problems.** Tell your healthcare provider if your child develops blurred vision or other vision problems during treatment with KHINDIVI. Your healthcare provider may have your child see an eye doctor.
- **Gastrointestinal problems.** KHINDIVI can affect your child's stomach or intestine. Tell your healthcare provider if your child has gastrointestinal illnesses such as stomach or intestinal ulcers, infections, or gastrointestinal surgery.
- Risk of Kaposi's Sarcoma if your child takes too much KHINDIVI. Kaposi's Sarcoma has happened in people who receive corticosteroid therapy, most often for treatment of long-lasting (chronic) conditions. Taking too much KHINDIVI over a long period of time can increase your child's risk of developing Kaposi's Sarcoma.
- **Vaccinations.** Administration of live vaccine may be acceptable while taking KHINDIVI.

## The most common side effects of KHINDIVI include:

• fluid retention

- change in blood sugar (glucose) tolerance
- increase in blood pressure

- behavioral and mood changes
- (glucose) toleranceincreased appetite and weight gain

These are not all the possible side effects of KHINDIVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

## How should I store KHINDIVI?

- Store KHINDIVI in the refrigerator between 36°F to 46°F (2°C to 8°C) or at room temperature between 68°F to 77°F (20°C to 25°C).
- Protect from light and heat.
- After the bottle has been opened, use KHINDIVI within 120 days. Throw away any KHINDIVI that has not been used within 120 days after the bottle has been opened.

# Keep KHINDIVI and all medicines out of the reach of children.

## General information about the safe and effective use of KHINDIVI.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use KHINDIVI for a condition for which it was not prescribed. Do not give KHINDIVI to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about KHINDIVI that is written for health professionals.

## What are the ingredients in KHINDIVI?

Active ingredient: hydrocortisone

**Inactive ingredients**: berry flavor, butylated hydroxyanisole, ethyl maltol, glycerin, methylparaben, propylparaben, polyethylene glycol, propylene glycol, and sucralose. KHINDIVI is manufactured for Eton Pharmaceuticals, Inc. by Tulex Pharmaceuticals, Inc., 5 Cedarbrook Dr., Cranbury, NI 08512, USA.

KHINDIVI® is a registered trademark of Eton Pharmaceuticals, Inc.

KHINDIVI is covered by the following US patent: 11,904,046.

For more information, go to www.KHINDIVI.com or call **1-833-343-2500.** 

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Issued: 06/2025

#### **PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label**

NDC-71863-116-16 Rx Only

Khindivi (hydrocortisone) oral solution

1 mg/mL

For Oral Use Only

ATTENTION PHARMACIST: Dispense the following to each patient:

- Accompanying Medication Guide
- Oral Dosing Syringe

16 oz (473 mL)

Manufactured for: eTon PHARMACEUTICALS Deer Park, IL 60010, USA

LAB-1613-v3 Rev. 05/2025

NDC-71863-116-16 Khino (hydrocortis oral solutio 1 mg/ml	Rx Only One) n	Each Store to 30 room Ensu Reco Date Disc	mL contains 1 mg of hydrod e at 2°C to 25°C (36°F to 77°F) 0°C (86°F) [see USP refrigerate in temperature]. Protect from are seal is present and intact f ommended Dosage: See pres e First Opened:/ ard unused portion 120 da	ortisone. Excursions permitted and controlled light and heat. before using. cribing information. _/ ys after first
		ope	ning.	· · · · · · · · · · · · · · · · · · ·
For Oral Use O	nly			
ATTENTION PHARMACIST: Dispense the following to e • Accompanying Medicati • Oral Dosing Syringe	Keep this and all medications out of the reach of children.			
16 oz (473 mL) Manufactured fo ETON P H A R M A C E U T I C Deer Park, IL 60010,	r: : A L S USA	GTIM	1: 12345678901234 NDC: 71863-116-16 S/N: 123456789012 EXP: YYYY-MM-DD LOT: 1234ABC	
LAB-1613-v3	Rev. 05/2025			
<b>KHINDIVI</b> hydrocortisone solution				
Product Information				
Product Type	HUMAN PRESCRIPTIO	N DRUG	Item Code (Source)	NDC:71863-116
Route of Administration	ORAL			
Active Ingredient/Active	Moiety			

Ingredient Name	Basis of Strength	Strength
Hydrocortisone (UNII: W4X0X7BPJ) (Hydrocortisone - UNII:	W4X0X7BPJ) Hydrocortisone	1 mg in 1 mL

Inactive Ingredients

Ingredient Name

Strength

PC	LYETHYLENE G	LYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)							
Pr	Propylene Glycol (UNII: 6DC9Q167V3)								
Methylparaben (UNII: A2I8C7HI9T)									
Pr									
Su	cralose (UNII: 96	SK6UQ3ZD4)							
Et	n <b>yi Maltol</b> (UNII:	L6Q8K29L05)							
Bu	tylated Hydroxy	yanisole (UNII: REK4960K2U)							
Gl	<b>/cerin</b> (UNII: PDC	6A3C0OX)							
Pı	oduct Chara	acteristics							
Co	lor	YELLOW (colorless to slightly yellow)		Score					
Sh	аре	Size							
Fla	vor	BERRY		Imprint C	ode				
Co	ntains								
_									
Pa	ackaging								
#	ltem Code	Package Description		Marketing Start Date	Marketing E Date	Ind			
1	NDC:71863-116- 16	1 mL in 1 BOTTLE; Type 0: Not a Combination Product	06	/02/2025					
Μ	arketing	Information							
	Marketing Category	Application Number or Monograph Citation		Marketing Start Date	Marketing   Date	End			
ND	A	NDA218980		06/02/2025					

La	be	ler -	Eton	Pharma	ceuticals,	Inc.	(08087	0465)
----	----	-------	------	--------	------------	------	--------	-------

# Establishment

Name	Address	ID/FEI	Business Operations
Tulex Pharmaceuticals, Inc.		080119240	MANUFACTURE(71863-116) , PACK(71863-116) , LABEL(71863-116) , ANALYSIS(71863-116)

## Establishment

Name	Address	ID/FEI	<b>Business Operations</b>
New Jersey Laboratories		063155238	ANALYSIS(71863-116)

## Establishment

Name	Address	ID/FEI	<b>Business Operations</b>
Perritt Laboratories, Inc.		077106284	ANALYSIS(71863-116)

Eton Pharmaceuticals, Inc.